Aristotle University Of Thessaloniki (AUTH)
Γονιδιακή ταυτοποίηση πρωτοπαθούς επίκτητης ανεπάρκειας λακτάσης στη Βόρειο Ελλάδα
Abstract
dc:descriptionAbout 70% of world population shows decreased lactase activity. People who have this disorder cannot ingest lactose and so avoid milk and products which are the main source of. Lactose is a disaccharide unique, found only in the milk of mammals, particularly in humans is the main energy source of infant. Lactose is broken down into glucose and galactose by lactase, an enzyme of the brush border epithelial cells of the intestinal mucosa. Lactase is a special b-galactosidase, which is a unique enzyme because of its structure. This enzyme contains two active sites within the same polypeptide chain, a region hydrolyzes lactose, and is called lactase hydrolyses and the other an a-glucosidase and called florizini. The full name of the enzyme lactase is hydrolase lactase-florizini (LPH). The lactase activity is very high at birth and during lactation, when milk is the sole source of food for the infant, at weaning and just before adulthood is drastically reduced by 80% - 90%. This reduction occurs in most populations characterized as primary lactase deficiency (P.E.A.L) and is the most common genetically determined lack of disaccharidase. The prevalence of P.E.A.L in Europe is 30% to 60%. The lower incidence found in Western Europe and particularly in the United Kingdom. In Asia P.E.A.L shows very high rate of 60% to 100%, except for a Bedouin tribes in Jordan and Saudi Arabia. Similar is the frequency and Africa. In Greece, primary acquired lactase deficiency has not been investigated extensively. There are reports that the prevalence varies from 45% in North and Central Greece, as 75% in the islands and the Peloponnese. The deficiency of lactase results in lactose unbroken presence in the small intestine. The lactose generates an osmotic load that drags water into the intestinal lumen increases peristalsis, and extend the malabsorption of disaccharides, causing clinical symptoms. Then the fermentation is applied to the undigested lactose by the colonic microflora exacerbate symptoms. In particular, the continuum lactose causes bloating, gurgling, abdominal pain, abnormal stools. To avoid these clinical signs people with lactase deficiency avoid milk and dairy products. But these products are the major source for calcium, which is necessary for normal bone growth. It has been observed mainly in postmenopausal women increased incidence of osteoporosis is associated with the acquired type adult lactase. The diagnosis of lactase deficiency is a test of Breath H2 test. Since 1990 the detection of a polymorphism laid the basis for gene diagnosis. The polymorphism Cytosine/thymidine (CT-13910) located in intron 13 of MCM6 gene which is adjacent to the gene for lactase at the end of the last -5. In particular, the CT-13910 is associated with lactase deficiency in homozygous form for cytosine CC while heterozygosity for cytosine/thymidine shows moderate lactase activity, i.e. the CT operators have a partial capacity to ingest lactose. Purpose Given the difference in frequency of P.E.A.L between geographic areas was necessary to search for polymorphism in most areas especially in those where the frequency is high. Greece is one of the countries where, despite the high incidence of lactase deficiency is not evidence for the polymorphism. For this purpose it was decided to conduct this study in order to detect CT-13910 polymorphism in children with primary acquired lactase deficiency in Northern Greece. Materials and Methods: 56 children with clinical symptoms of lactase deficiency underwent Breath H2 test, polymorphism detection and compared with 76 healthy children, who were also in BT and detection of polymorphism. Results: Based on the results of BH2 created two groups A1 and A2. Were A1 (27) twenty-seven children with a clinical picture compatible with lactase deficiency and a positive test H2, while A2 contains (29) twenty-nine children with the same clinical picture but normal test H2.The audit revealed polymorphisms: the A1 group 24/27 children were homozygous for the polymorphism and CC-13910 3/27 heterozygotes CT-13910. In group A2: 29, from children with clinical test but negative hydrogen, the 24 were homozygous for the CC-13910 and 5 heterozygotes CT-13910. Overall the group of patients CC-13910 genotype had 48 children and 8 had CT-13910.In groups A1 and A2 (with symptoms) the frequency of polymorphism were: 85% for CC and 14.29% for CT. The TT polymorphism was not detected in any patient. About the age of the average age of children with clinical symptoms but negative test H2 is: 7,33 ± 3,47, while the average age of children with clinical symptoms and positive test while H2 was 10,86 ± 6,57. The positive tests H2 correspond to older ages (p = 0,015). In the control group (non-symptomatic) H2 tests was negative and the frequency of polymorphism were: 63/76 children had a rate of 82.89% CC and 13/76 children were heterozygous CT at the rate of 17.11%. As shown above, the frequency of the CC group patients and in healthy children is not significantly different p=0,662, also for the CT-13910 is not significantly different p=0,796.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Κώτση, Ελένη
Subjects
dc:subject × 19Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/35003